The Korean drugmaker posted 23.7 billion won in operating profit, crediting Wegovy, which it co-promotes with Novo Nordisk, and the eye drug Eylea.
Recap by typeshit. Full story at Seoul Economic Daily.
Tara Wider has spent about five years posting on holistic beauty and women's wellness, building a following of women her age on social media.
Brown says diet and exercise still matter, but argues that shaming people for treating obesity with medication has never made anyone healthier.
A short share on growing GLP-1 use in the US, with no figures or sources attached. Thin on detail beyond the headline itself.
A new survey covered by Chain Store Age tracks how GLP-1 users are shifting their food spending from restaurants toward grocery stores.
A new market report values the sector at $97.5 billion in 2025 and expects oral and multi-pathway drugs to grow fastest as Medicare coverage starts in mid-2026.
Retrospective REDEFINE 1 analyses in 2,309 women showed 25.0% average weight loss on CagriSema at 68 weeks, per Novo, versus 3.0% on placebo.
Loading…